Who Paid My Doc
Nathan Swain
Physical Medicine & Rehabilitation Flagstaff, AZ Medical Doctor
NPI 1306167531 CMS profile 598413
525 N Switzer Canyon Dr, Flagstaff, AZ 86001
General payments
$24,133
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$8,842
Through program year 2025, Nathan Swain of Flagstaff, AZ is reported in the CMS Open Payments database as having received $24,133 across 157 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,842 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,441 | 32 | |
| 2024 | General | $16,037 | 58 | |
| 2023 | General | $870 | 16 | |
| 2022 | General | $1,910 | 35 | |
| 2021 | General | $874 | 16 |
Beside peers
- Nathan Swain
- Physical Medicine & Rehabilitation median
- Middle half of Physical Medicine & Rehabilitation
- National median
In program year 2025, general payments to Nathan Swain were reported at $4,441. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.
Show as a table
| Year | Nathan Swain | Physical Medicine & Rehabilitation median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $133 | $45–$390 | $163 |
| 2020 | $0 | $88 | $29–$272 | $114 |
| 2021 | $874 | $116 | $33–$360 | $132 |
| 2022 | $1,910 | $123 | $40–$378 | $149 |
| 2023 | $870 | $131 | $43–$396 | $160 |
| 2024 | $16,037 | $141 | $45–$409 | $164 |
| 2025 | $4,441 | $139 | $48–$410 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
842
Drug cost
$19,702
Branded share of claims
11.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Belbuca Buprenorphine Hcl | Brand | 13 | $7,150 | |
| Celecoxib | Generic | 98 | $4,637 | |
| Gabapentin | Generic | 220 | $4,428 | |
| Meloxicam | Generic | 298 | $1,456 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 59 | $922 | |
| Cyclobenzaprine Hcl | Generic | 46 | $474 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 22 | $232 | |
| Methylprednisolone | Generic | 31 | $173 | |
| Tramadol Hcl | Generic | 28 | $133 | |
| Oxycodone Hcl | Generic | 14 | $88 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 526 Part D prescribers listed as Osteopathic Manipulative Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 73 billing codesPaid by Medicare
$266,334
Medicare patients
876
Services billed
4,618
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 67% | |
| Diabetes | 24% | |
| Osteoporosis | 24% | |
| Ischemic heart disease | 21% | |
| Chronic kidney disease | 18% | |
| Depression | 18% | |
| Atrial fibrillation | 12% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 | Office | 11 | 900 | $4,496 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 109 | 578 | $429 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
157 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Physical Medicine & Rehabilitation in Arizona
Marshall Meier
Physical Medicine & Rehabilitation · Flagstaff, AZ
Azmi Nasser
Physical Medicine & Rehabilitation · Phoenix, AZ
Christina Kwasnica
Physical Medicine & Rehabilitation · Phoenix, AZ
Thomas Coury
Physical Medicine & Rehabilitation · Tucson, AZ
Keikhosrow Mosallaie
Physical Medicine & Rehabilitation · Phoenix, AZ
Jacob Rohrs
Physical Medicine & Rehabilitation · Scottsdale, AZ
Related records
Physical Medicine & Rehabilitation in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Physical Medicine & Rehabilitation
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.